ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy
July 23, 2024Research and Development GSK, HIV, HIV/AIDS, ViiV Healthcare, maintenance therapy
GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with Pfizer and Shionogi as shareholders, …
ViroCell Biologics signs Master Services Agreement with NCI-designated cancer centre
July 23, 2024Business Services Cancer, Oncology, ViroCell Biologics, agreement
ViroCell Biologics has announced that it has signed a five-year Master Services Agreement (MSA) with a prominent US-based NCI-designated cancer …
60 Degrees Pharmaceuticals signs clinical trial agreements with sites for babesiosis study
July 22, 2024Medical Communications 60 Degrees Pharmaceuticals, Pharmacy, babesiosis, clinical trials
60 Degrees Pharmaceuticals has announced that it has signed clinical trial agreements with all three of its planned trial sites …
Results from Sanofi’s ALTUVIIIO XTEND-Kids phase 3 trial published in NEJM
July 22, 2024Research and Development Altuviiio, Haematology, Sanofi, haemophilia
Sanofi has announced that full results from the XTEND-Kids phase 3 study were published in The New England Journal of …
GSK’s application for Blenrep for MM treatment accepted for EMA review
July 19, 2024Medical Communications Blenrep, EMA, GSK, Oncology
GSK has announced that the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for Blenrep (belantamab mafodotin) …
Brainomix and Boehringer Ingelheim enter strategic partnership
July 19, 2024Research and Development Boehringer Ingelheim, Brainomix, Pharmacy, fibrosing lung disease, partnership
Brainomix has announced that it has entered into a strategic partnership with Boehringer Ingelheim for a collaborative programme surrounding the …
FDA accepts Atara Biotherapeutics’ Tab-Cel for priority review
July 18, 2024Medical Communications Atara Biotherapeutics, FDA, Virology, priority review
Atara Biotherapeutics has announced that the US Food and Drug Administration (FDA) has accepted the filing of its Biologics License …
China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
July 18, 2024Medical Communications China, Everest Medicines, NMPA, Nephrology
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …
Loci Orthopaedics announces €12.8m series A financing
July 17, 2024Business Services Financing, Musculo-skeletal disorder, investment, loci orthopaedics
Loci Orthopaedics has announced the successful closing of an oversubscribed €12.8m series A financing, which was led by new investors …
Renalys Pharma closes ¥6bn series A financing for kidney disease treatments in Asia
July 17, 2024Business Services Financing, Nephrology, kidney disease, renalys Pharma
Renalys Pharma has announced that it has completed ¥6bn series A financing, which was led by Catalys Pacific and SR …
Camurus shares phase 3 results from ACROINNOVA 2 study
July 16, 2024Research and Development Camurus, Pharmacy, acromegaly, clinical trial, injection
Camurus has announced positive results from its 52-week phase 3 open-label ACROINNOVA 2 study, which assessed the safety and efficacy …
NICE recommends digital tech for ADHD diagnosis in children and young people
July 16, 2024Medical Communications ADHD, Diagnostics, NICE
The National Institute for Health and Care Excellence (NICE) has announced that its diagnostics advisory committee has recommended the QbTest …
AI-powered prognosis test company Spotlight Medical secures €6.2m in seed funding
July 15, 2024Research and Development Oncology, Precision Medicine, Spotlight Medical, artificial intelligence, oncology, seed funding
Start-up Spotlight Medical has announced it has raised €6.2m in a seed funding round led by Kurma Partners and Heal Capital. …
ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models
July 15, 2024Research and Development Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug
Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies …
Pfizer selects once-daily obesity drug for advancement
July 12, 2024Research and Development Obesity, Pfizer Inc, clinical trials, obesity
Pfizer has announced the selection of its preferred once-daily modified release formulation for danuglipron, with a plan to conduct dose …
Imidex and Spesana collaborate over impact of AI in lung nodule and mass detection
July 12, 2024Research and Development Imidex, Oncology, Spesana, artificial intelligence, cancer detection, lung cancer
Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s …
Aspect Biosystems announces partnership with governments of Canada and British Columbia
July 11, 2024Business Services Aspect Biosciences, Pharmacy, government, investment
Aspect Biosystems has announced that it has entered into an agreement with the governments of Canada and British Columbia, under …
Biophytis gains IND approval from FDA for obesity study
July 11, 2024Medical Communications Biophytis, IND, Obesity, clinical trial, obesity
Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …
Pharmaxo acquired by Icon Group in strategic partnership
July 10, 2024Business Services Oncology, Pharmaxo, acquisition, strategic parnership
Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global …
Certara to acquire Chemaxon for drug discovery portfolio
July 10, 2024Business Services Certara, Chemaxon, Pharmacy, acquisition, drug discovery
Certara and Chemaxon have announced that they have signed a definitive agreement under which Certara will acquire Chemaxon. The deal …
Latest content
FibroFind appoints Lee Borthwick as CEO
